 Antonio Jimeno-Largo
Concepts (77)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Triazines | 2 | 2021 | 43 | 0.840 |
Why?
| | Oncogene Proteins, Viral | 1 | 2023 | 22 | 0.820 |
Why?
| | Benzamides | 2 | 2021 | 217 | 0.790 |
Why?
| | Biliary Tract Neoplasms | 1 | 2021 | 30 | 0.700 |
Why?
| | Carboplatin | 1 | 2021 | 143 | 0.690 |
Why?
| | Gastrointestinal Stromal Tumors | 1 | 2020 | 38 | 0.660 |
Why?
| | Hyaluronan Receptors | 1 | 2020 | 103 | 0.660 |
Why?
| | Paclitaxel | 1 | 2021 | 227 | 0.650 |
Why?
| | Pyrroles | 1 | 2020 | 211 | 0.630 |
Why?
| | Papillomavirus Infections | 1 | 2023 | 324 | 0.610 |
Why?
| | Pyridones | 1 | 2020 | 168 | 0.600 |
Why?
| | Hematologic Neoplasms | 1 | 2020 | 155 | 0.570 |
Why?
| | Pyrazoles | 1 | 2020 | 423 | 0.530 |
Why?
| | Neoplasms | 2 | 2023 | 2644 | 0.520 |
Why?
| | Neoplastic Stem Cells | 1 | 2020 | 397 | 0.500 |
Why?
| | Immunotherapy | 1 | 2020 | 640 | 0.490 |
Why?
| | Nanoparticles | 1 | 2021 | 484 | 0.470 |
Why?
| | Head and Neck Neoplasms | 1 | 2020 | 604 | 0.460 |
Why?
| | Melanoma | 1 | 2020 | 757 | 0.420 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 1078 | 0.380 |
Why?
| | Lung Neoplasms | 1 | 2021 | 2491 | 0.280 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2020 | 864 | 0.270 |
Why?
| | Clinical Trials as Topic | 2 | 2020 | 1043 | 0.240 |
Why?
| | Papillomavirus E7 Proteins | 1 | 2023 | 11 | 0.210 |
Why?
| | HLA-A Antigens | 1 | 2023 | 55 | 0.200 |
Why?
| | Human papillomavirus 16 | 1 | 2023 | 35 | 0.200 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2021 | 1683 | 0.180 |
Why?
| | Zinc Finger E-box-Binding Homeobox 1 | 1 | 2020 | 24 | 0.170 |
Why?
| | Maximum Tolerated Dose | 1 | 2021 | 198 | 0.170 |
Why?
| | Bendamustine Hydrochloride | 1 | 2020 | 13 | 0.170 |
Why?
| | Feedback, Physiological | 1 | 2020 | 77 | 0.170 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2021 | 75 | 0.170 |
Why?
| | Thymus Gland | 1 | 2021 | 313 | 0.170 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2020 | 67 | 0.170 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 1 | 2020 | 51 | 0.170 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2020 | 44 | 0.170 |
Why?
| | Leukocytes, Mononuclear | 1 | 2023 | 556 | 0.160 |
Why?
| | SOXB1 Transcription Factors | 1 | 2020 | 61 | 0.160 |
Why?
| | Biphenyl Compounds | 1 | 2020 | 63 | 0.160 |
Why?
| | Morpholines | 1 | 2020 | 121 | 0.160 |
Why?
| | Imidazoles | 1 | 2021 | 239 | 0.160 |
Why?
| | Gene Silencing | 1 | 2020 | 193 | 0.160 |
Why?
| | Mutation | 2 | 2021 | 3953 | 0.160 |
Why?
| | Rituximab | 1 | 2020 | 178 | 0.150 |
Why?
| | Lymphoma, B-Cell | 1 | 2020 | 105 | 0.150 |
Why?
| | Mice, Inbred NOD | 1 | 2020 | 601 | 0.150 |
Why?
| | Immunoconjugates | 1 | 2020 | 114 | 0.150 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2021 | 250 | 0.150 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2020 | 365 | 0.150 |
Why?
| | Hyaluronic Acid | 1 | 2020 | 221 | 0.150 |
Why?
| | Monocytes | 1 | 2020 | 561 | 0.140 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2020 | 429 | 0.140 |
Why?
| | Humans | 9 | 2023 | 136783 | 0.130 |
Why?
| | Cell Cycle Proteins | 1 | 2020 | 611 | 0.130 |
Why?
| | Tumor Microenvironment | 1 | 2020 | 671 | 0.130 |
Why?
| | Epigenesis, Genetic | 1 | 2020 | 658 | 0.120 |
Why?
| | Protein Kinase Inhibitors | 1 | 2020 | 916 | 0.110 |
Why?
| | Antibodies, Monoclonal | 1 | 2020 | 1428 | 0.100 |
Why?
| | T-Lymphocytes | 1 | 2021 | 1998 | 0.100 |
Why?
| | Cell Line, Tumor | 1 | 2020 | 3399 | 0.100 |
Why?
| | Cohort Studies | 1 | 2021 | 5718 | 0.080 |
Why?
| | Disease Models, Animal | 1 | 2020 | 4279 | 0.080 |
Why?
| | Animals | 3 | 2021 | 36768 | 0.080 |
Why?
| | Mice | 2 | 2021 | 17731 | 0.060 |
Why?
| | Treatment Outcome | 1 | 2021 | 10764 | 0.060 |
Why?
| | Male | 2 | 2021 | 67361 | 0.050 |
Why?
| | United States | 1 | 2020 | 14660 | 0.050 |
Why?
| | Female | 2 | 2021 | 72840 | 0.050 |
Why?
| | Aged | 1 | 2021 | 23729 | 0.040 |
Why?
| | Adult | 2 | 2021 | 37616 | 0.040 |
Why?
| | Middle Aged | 1 | 2021 | 33200 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 451 | 0.040 |
Why?
| | Epithelial Cells | 1 | 2021 | 1093 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2020 | 1455 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 1055 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2021 | 4194 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2021 | 1980 | 0.030 |
Why?
|
|
Jimeno-Largo's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|